COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,635 Articles (22,913 medRxiv, 8,722 bioRxiv)

Most recent first Previous |  Page 974: Articles 9731-9740  | Next

Symptoms and severity in vaccinated and unvaccinated patients hospitalised with SARS-CoV-2 delta (B.1.617.2) variant infection
Epaulard, O., Abgrall, S., Lefebvre, M., Faucher, J.-F., Michon, J., Frentiu, E., Janssen, C., Charbonnier, G., Fresse, A., Laurent, S., Sandjakian, L., Casez, P., Mahamat, A., Beraud, G.
10.1101/2022.02.08.22270506 — Posted: 2022-02-09
N-acylethanolamine acid amide hydrolase is a novel target for drugs against SARS-CoV-2 and Zika virus
Lai, M., La Rocca, V., Amato, R., Iacono, E., filipponi, c., Catelli, E., Bogani, L., Fonnesu, R., lottini, g., De Carli, A., Mengozzi, A., Masi, S., Quaranta, P., Spezia, P. G., Freer, G., Lenzi, P., Fornai, F., Piomelli, D., Pistello, M.
10.1101/2022.02.08.479661 — Posted: 2022-02-09
SARS-CoV-2 ORF6 disrupts innate immune signalling by inhibiting cellular mRNA export
Hall, R., Guedan, A., Yap, M. W., Young, G. R., Harvey, R., Stoye, J. P., Bishop, K. N.
10.1101/2022.02.08.479664 — Posted: 2022-02-09
Auto-Immunoproteomics Analysis of COVID-19 ICU Patients Revealed Increased Levels of Autoantibodies Related to Male Reproductive System
Schmidt, F., Abdesselem, H. B., Suhre, K., Sohail, m. u., Al-Nesf, M., Bensmail, I., Mashod, F., Sarwath, H., Bernhardt, J., Tan, T.-M., Morris, P. E., Schenck, E. J., Price, D., Vaikath, N., Mohamed-Ali, V., Al-Maadheedh, M., Arredouani, A., Decock, J. V., Blackburn, J., Choi, A. M. K., El-Agnaf, O. M. A.
10.1101/2022.02.09.479669 — Posted: 2022-02-09
Narrow transmission bottlenecks and limited within-host viral diversity during a SARS-CoV-2 outbreak on a fishing boat
Hannon, W. H., Roychoudhury, P., Xie, H., Shrestha, L., Addetia, A., Jerome, K. R., Greninger, A. L., Bloom, J. D.
10.1101/2022.02.09.479546 — Posted: 2022-02-09
Aerosol Formation During Processing of Potentially Infectious Samples on Roche Immunochemistry Analyzers (cobas e analyzers) and in an End-to-End Laboratory Workflow to Model SARS-CoV-2 Infection Risk for Laboratory Operators
Burghardt, G. V., Eckl, M., Huether, D., Larbolette, O. H. D., Lo Faso, A., Ofenloch-Haehnle, B. R., Riesch, M. A., Herb, R. A.
10.1101/2022.02.08.479519 — Posted: 2022-02-09
The oral drug nitazoxanide restricts SARS-CoV-2 infection and attenuates disease pathogenesis in Syrian hamsters
Miorin, L., Mire, C. E., Ranjbar, S., Hume, A. J., Huang, J., Crossland, N. A., White, K. M., Laporte, M., Kehrer, T., Haridas, V., Moreno, E., Nambu, A., Jangra, S., Cupic, A., Dejosez, M., Abo, K. A., Tseng, A. E., Werder, R. B., Rathnasinghe, R., Mutetwa, T., Ramos, I., Sainz de Aja, J., Garcia de Alba Rivas, C., Schotsaert, M., Corley, R. B., Falvo, J. V., Fernandez-Sesma, A., Kim, C., Rossignol, J.-F., Wilson, A. A., Zwaka, T., Kotton, D. N., Mühlberger, E., García-Sastre, A., Goldfeld, A. E.
10.1101/2022.02.08.479634 — Posted: 2022-02-09
Olverembatinib inhibits SARS-CoV-2-Omicron variant-mediated cytokine release
Chan, M., Holland, E., Gujral, T.
10.1101/2022.02.07.479443 — Posted: 2022-02-09
Plasticity in structure and assembly of SARS-CoV-2 nucleocapsid protein
Zhao, H., Nguyen, A., Wu, D., Li, Y., Hassan, S. A., Chen, J., Shroff, H., Piszczek, G., Schuck, P.
10.1101/2022.02.08.479556 — Posted: 2022-02-09
Designing effective siRNAs to silence structural proteins associated genes of Indian SARS-CoV-2 strains: an in silico approach
Madanagopal, P., Muthukumar, H., Thiruvengadam, K.
10.1101/2022.02.08.479559 — Posted: 2022-02-09

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).